Drugs / HF158K1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05861895 | Dec 2023 → Jun 2027 expected | — | HighField Biopharmaceuticals Corporation | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HF158K1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05861895 ↗ |
| Known as | doxorubicin hydrochloride | “HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor” NCT05861895 ↗ |
| Action | Inhibit | “an anthracycline topoisomerase inhibitor” NCT05861895 ↗ |
| Route | Intravenous | “is administered through intravenous infusion” NCT05861895 ↗ |